Incidence and risk of developing photosensitivity with targeted anticancer therapies.
作者信息
Ciccolini Kathryn T, Kim Joseph, Chaudhari Soham P, Lucas Anna Skripnik, Benhuri Benjamin, Duran Juanita, Wu Shenhong, Lacouture Mario E
机构信息
Department of Dermatology, Memorial Sloan Kettering Cancer Center, New York, New York.
SUNY Downstate College of Medicine, Brooklyn, New York.
出版信息
J Am Acad Dermatol. 2019 Oct;81(4):1009-1011. doi: 10.1016/j.jaad.2019.01.077. Epub 2019 Feb 5.
Abstract
摘要
相似文献
1
Incidence and risk of developing photosensitivity with targeted anticancer therapies.
J Am Acad Dermatol. 2019 Oct;81(4):1009-1011. doi: 10.1016/j.jaad.2019.01.077. Epub 2019 Feb 5.
2
Severe photosensitivity reaction to vandetanib.
J Clin Oncol. 2009 Sep 20;27(27):e114-5. doi: 10.1200/JCO.2009.21.8479. Epub 2009 Jun 29.
3
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
J Immunother Cancer. 2019 Jan 8;7(1):4. doi: 10.1186/s40425-018-0475-y.
4
Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma.
Clin Exp Dermatol. 2019 Apr;44(3):243-251. doi: 10.1111/ced.13751. Epub 2018 Oct 2.
5
Neurotoxicity induced by targeted therapies in patients treated for metastatic melanoma.
Eur J Cancer. 2019 Apr;111:8-11. doi: 10.1016/j.ejca.2019.01.017. Epub 2019 Feb 22.
6
Nivolumab therapy before vemurafenib administration induces a severe skin rash.
J Eur Acad Dermatol Venereol. 2017 Mar;31(3):e169-e171. doi: 10.1111/jdv.13892. Epub 2016 Aug 22.
7
Cutaneous pigmentation after photosensitivity induced by vandetanib therapy.
Arch Dermatol. 2009 Aug;145(8):923-5. doi: 10.1001/archdermatol.2009.177.
8
Photo-induced erythema multiforme associated with vandetanib administration.
J Am Acad Dermatol. 2014 Oct;71(4):e142-4. doi: 10.1016/j.jaad.2014.05.003.
9
Cutaneous adverse reactions to anti-PD-1 treatment-A systematic review.
J Am Acad Dermatol. 2020 Nov;83(5):1415-1424. doi: 10.1016/j.jaad.2020.04.058. Epub 2020 Apr 19.
10
Gastric perforation due to nivolumab related tumor flare.
Indian J Cancer. 2019 Oct-Dec;56(4):374-375. doi: 10.4103/ijc.IJC_776_18.
引用本文的文献
1
Sintilimab-induced photodistributed bullous pemphigoid: A case report.
Medicine (Baltimore). 2025 Feb 7;104(6):e41448. doi: 10.1097/MD.0000000000041448.
2
Photosensitivity From Avapritinib: Pharamacovigilance Analysis.
JMIR Dermatol. 2022 Aug 10;5(3):e39229. doi: 10.2196/39229.
3
Photosensitive rash induced by nivolumab.
An Bras Dermatol. 2022 Sep-Oct;97(5):648-650. doi: 10.1016/j.abd.2021.07.007. Epub 2022 Jul 7.
4
Anticancer treatments and photosensitivity.
J Eur Acad Dermatol Venereol. 2022 Jun;36 Suppl 6(Suppl 6):51-58. doi: 10.1111/jdv.18200.
5
Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.
An Bras Dermatol. 2022 Jan-Feb;97(1):14-21. doi: 10.1016/j.abd.2021.05.007. Epub 2021 Nov 26.
本文引用的文献
1
Nivolumab in previously untreated melanoma without BRAF mutation.
N Engl J Med. 2015 Jan 22;372(4):320-30. doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16.
2
Improved overall survival in melanoma with combined dabrafenib and trametinib.
N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.
3
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Lancet Oncol. 2012 Sep;13(9):897-905. doi: 10.1016/S1470-2045(12)70335-2. Epub 2012 Aug 14.
4
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
N Engl J Med. 2012 Feb 23;366(8):707-14. doi: 10.1056/NEJMoa1112302.
5
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5.
Zotero 插件